IMU-935 is less effective than a placebo, Immunic shares plummet
ADC评论
October 22, 2022
On October 20, Immunic announced that its Phase Ib clinical trial of its RORγt inverse agonist IMU-935 in the treatment of psoriasis failed to meet
